MENU
Showcases Stock ranks Forex

Evofem Biosciences Inc (EVFM)
0.8001  -0.143 (-15.19%) 08-08 16:00
Open: 0.9214 Pre. Close: 0.9434
High: 0.9256 Low: 0.79
Volume: 18,709,388 Market Cap: 28M
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 0.931 - 0.935 0.935 - 0.939
Low: 0.78 - 0.785 0.785 - 0.788
Close: 0.793 - 0.8 0.8 - 0.806
Stock Technical Analysis
Overall:     
Target: Six months: 1.44
One year: 1.83
Support: Support1: 0.69
Support2: 0.57
Resistance: Resistance1: 1.23
Resistance2: 1.57
Pivot: 0.83
Moving Averages: MA(5): 0.86
MA(20): 0.89
MA(100): 1.80
MA(250): 5.76
MACD: MACD(12,26): -0.02
Signal(12,26,9): -0.02
%K %D: %K(14,3): 46.60
%D(3): 44.33
RSI: RSI(14): 46.28
52-Week: High: 14.61
Low: 0.275
Change(%): -92.1
Average Vol(K): 3-Month: 37179
10-Days: 15972
Price, MAs and Bollinger Bands
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.

[ EVFM ] has closed above bottom band by 38.7%. Bollinger Bands are 80.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
Stock chart
Stock News
Thu, 04 Aug 2022
Evofem Biosciences Announces Strong Second Quarter 2022 Financial Results and Affirms 2022 Guidance - PR Newswire

Fri, 29 Jul 2022
Evofem Biosciences Commends Tri-Agencies for Clarifying that Contraceptives Must be Covered at No Cost to Individuals - Yahoo Finance

Tue, 26 Jul 2022
Evofem's House Rules Campaign Featuring Annie Murphy Receives Significant Industry Recognition - PR Newswire

Sat, 23 Jul 2022
Evofem Biosciences (NASDAQ:EVFM) Shares Cross Above 50-Day Moving Average of $0.68 - Defense World

Fri, 22 Jul 2022
Evofem Biosciences Applauds U.S. House of Representatives for Passing The Right to Contraception Act - PR Newswire

Thu, 21 Jul 2022
Evofem Biosciences (EVFM) Stock: Why It Increased Over 24% Today - Pulse 2.0

Financial Analysis
Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M)
Shares Float (M) 35.38
% Held by Insiders 11160000.00
% Held by Institutions 8.88
Shares Short (K) 2110
Shares Short Prior Month (K)
Stock Financials
EPS -149760000.000
Book Value (p.s.)
Profit Margin
Operating Margin
Return on Assets (ttm) 324.5
Return on Equity (ttm) -147.3
Qtrly Rev. Growth 11390000.0
Gross Profit (p.s.)
Sales Per Share 0.030
EBITDA (p.s.) -1.007
Qtrly Earnings Growth -19.01
Operating Cash Flow (M)
Levered Free Cash Flow (M) -133.13
Stock Valuation
PE Ratio
PEG Ratio
Price to Book value
Price to Sales 26.97
Price to Cash Flow 0.13
Stock Dividends
Dividend
Dividend Yield
Dividend Growth 10990000.000

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android